- Home
- CABA vs IPHA Comparison
CABA vs IPHA Comparison
Compare CABA & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- IPHA
- Stock Information
- Founded
- CABA 2017
- IPHA 1999
- Country
- CABA United States
- IPHA France
- Employees
- CABA 167
- IPHA N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- CABA Health Care
- IPHA Health Care
- Exchange
- CABA Nasdaq
- IPHA Nasdaq
- Market Cap
- CABA 174.7M
- IPHA 160.1M
- IPO Year
- CABA 2019
- IPHA 2019
- Fundamental
- Price
- CABA $2.04
- IPHA $2.03
- Analyst Decision
- CABA Strong Buy
- IPHA Strong Buy
- Analyst Count
- CABA 8
- IPHA 1
- Target Price
- CABA $12.75
- IPHA $11.00
- AVG Volume (30 Days)
- CABA 1.3M
- IPHA 11.4K
- Earning Date
- CABA 11-13-2025
- IPHA 09-17-2025
- Dividend Yield
- CABA N/A
- IPHA N/A
- EPS Growth
- CABA N/A
- IPHA N/A
- EPS
- CABA N/A
- IPHA N/A
- Revenue
- CABA N/A
- IPHA $20,831,349.00
- Revenue This Year
- CABA N/A
- IPHA $350.96
- Revenue Next Year
- CABA N/A
- IPHA $32.92
- P/E Ratio
- CABA N/A
- IPHA N/A
- Revenue Growth
- CABA N/A
- IPHA N/A
- 52 Week Low
- CABA $0.99
- IPHA $1.29
- 52 Week High
- CABA $5.46
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- CABA 71.47
- IPHA 45.26
- Support Level
- CABA $1.63
- IPHA $1.93
- Resistance Level
- CABA $1.74
- IPHA $2.19
- Average True Range (ATR)
- CABA 0.12
- IPHA 0.11
- MACD
- CABA 0.05
- IPHA -0.01
- Stochastic Oscillator
- CABA 89.44
- IPHA 42.95
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.